 Home > Medical News > Latest Medical News > Target EGFR×HER3!

Target EGFR×HER3!

 Last Update: 2021-11-04
 Source: Internet
 Author: User

Tags

memantine drug class

cell parts

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

ArticleMedicine Guanlan

According to information published on the official website of the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China, the BL-B01D1 for injection declared by Bailey Pharmaceutical has obtained a clinical implied license and is intended to be developed for the treatment of locally advanced or metastatic epithelial tumors

Image source: CDE official website screenshot

Antibody-conjugated drugs are called "magic bullets" because they can accurately strike cancer cells

Traditional ADCs consist of three parts: monoclonal antibodies that target specific antigens on the tumor surface, cytotoxic drugs that can kill tumor cells, and linkers that connect cytotoxic drugs and antibodies

The BL-B01D1 approved by Baili Pharmaceutical this time is a dual-specific ADC targeting EGFR and HER3

According to Bailey's official website, the company plans to develop BL-B01D1 for the treatment of lung cancer, esophageal cancer, head and neck squamous cell carcinoma and other indications

The development of new antibody drugs is an important research and development direction of Baili Pharmaceutical

Reference materials:

[1] Center for Drug Evaluation of China National Medical Products Administration.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Overcoming EGFR mutation non-small cell lung cancer resistance First three total HER3 targeted ADC clinical results were positive.

09-30

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

Target EGFR×HER3!

Related Articles

Overcoming EGFR mutation non-small cell lung cancer resistance First three total HER3 targeted ADC clinical results were positive.